On March 6, 2026, Zealand Pharma's shares plunged more than 35% after the company released mid-stage trial results for its experimental weight-loss drug, petrelintide, which showed patients lost less weight than analysts had expected. The trial demonstrated an average weight reduction of 10.7% over 42 weeks, while analysts had anticipated a range between 13% and 20% weight loss [1]. This sharp decline marked Zealand's worst trading day ever and its lowest close since August 2023. Shares of Roche, Zealand's development partner for petrelintide, also fell 3% following the news [1].
CEO Adam Steensberg addressed investor concerns in an interview with CNBC, emphasizing that the trial was not optimized for maximum weight loss and defending the drug's real-world potential, particularly its tolerability and minimal side effects. Steensberg criticized the industry's focus on the "weight loss Olympics," where companies compete for the highest weight loss numbers, and argued that maintaining weight loss and tolerability are more important for patients in real-world settings [1]. He stated, "The world doesn't need these products that amount to very high rates of weight loss," referencing competitors Novo Nordisk and Eli Lilly. Steensberg expressed confidence that the industry would soon shift its focus toward tolerability, as many patients cannot tolerate the side effects of existing drugs in real-world use [1].
Zealand Pharma is positioning itself as a company focused on weight maintenance rather than rapid weight loss, aiming to differentiate itself in the lucrative weight-loss drug market, which is estimated to be worth as much as $150 billion by 2030 [1]. Despite the disappointing trial results, Steensberg remains "extremely certain" that industry priorities will change, and he called for an end to the "weight loss Olympics" [1].
CONCLUSION
Zealand Pharma's disappointing trial results for petrelintide triggered a sharp sell-off, with shares dropping over 35% and Roche's shares falling 3%. While the weight loss achieved was below analyst expectations, the company is emphasizing drug tolerability and weight maintenance as its differentiators. The market reacted negatively, but Zealand's leadership remains confident in a future industry shift toward patient-centric outcomes.